These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1510 related articles for article (PubMed ID: 33738806)

  • 21. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.
    Vitiello A; La Porta R; D'Aiuto V; Ferrara F
    Hum Immunol; 2021 Apr; 82(4):264-269. PubMed ID: 33632561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
    England JT; Abdulla A; Biggs CM; Lee AYY; Hay KA; Hoiland RL; Wellington CL; Sekhon M; Jamal S; Shojania K; Chen LYC
    Blood Rev; 2021 Jan; 45():100707. PubMed ID: 32425294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of the inflammatory response and megakaryocytes in COVID-19 infection.
    Battina HL; Alentado VJ; Srour EF; Moliterno AR; Kacena MA
    Exp Hematol; 2021 Dec; 104():32-39. PubMed ID: 34563606
    [No Abstract]   [Full Text] [Related]  

  • 25. Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy.
    Iovino L; Thur LA; Gnjatic S; Chapuis A; Milano F; Hill JA
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics.
    Woodruff TM; Shukla AK
    Trends Immunol; 2020 Nov; 41(11):965-967. PubMed ID: 33023856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong?
    Darif D; Hammi I; Kihel A; El Idrissi Saik I; Guessous F; Akarid K
    Microb Pathog; 2021 Apr; 153():104799. PubMed ID: 33609650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19: A collision of complement, coagulation and inflammatory pathways.
    Chauhan AJ; Wiffen LJ; Brown TP
    J Thromb Haemost; 2020 Sep; 18(9):2110-2117. PubMed ID: 32608159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.
    Skendros P; Mitsios A; Chrysanthopoulou A; Mastellos DC; Metallidis S; Rafailidis P; Ntinopoulou M; Sertaridou E; Tsironidou V; Tsigalou C; Tektonidou M; Konstantinidis T; Papagoras C; Mitroulis I; Germanidis G; Lambris JD; Ritis K
    J Clin Invest; 2020 Nov; 130(11):6151-6157. PubMed ID: 32759504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.
    Das A; Rana S
    Comput Biol Chem; 2021 Jun; 92():107482. PubMed ID: 33845430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients.
    Bonam SR; Kaveri SV; Sakuntabhai A; Gilardin L; Bayry J
    Cell Rep Med; 2020 May; 1(2):100016. PubMed ID: 32562483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cytokine storm-An appropriate, over-reactive response to SARS-CoV-2 or the wrong immune pathway?
    Bellgrau D; Modiano JF
    Scand J Immunol; 2021 Mar; 93(3):e12979. PubMed ID: 32991014
    [No Abstract]   [Full Text] [Related]  

  • 33. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
    Pinheiro MM; Fabbri A; Infante M
    Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunothrombosis in Acute Respiratory Dysfunction of COVID-19.
    Fang XZ; Wang YX; Xu JQ; He YJ; Peng ZK; Shang Y
    Front Immunol; 2021; 12():651545. PubMed ID: 34149692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting C5a: recent advances in drug discovery.
    Allegretti M; Moriconi A; Beccari AR; Di Bitondo R; Bizzarri C; Bertini R; Colotta F
    Curr Med Chem; 2005; 12(2):217-36. PubMed ID: 15638737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.
    Bonaventura A; Vecchié A; Dagna L; Martinod K; Dixon DL; Van Tassell BW; Dentali F; Montecucco F; Massberg S; Levi M; Abbate A
    Nat Rev Immunol; 2021 May; 21(5):319-329. PubMed ID: 33824483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Impaired Inflammatory and Innate Immune Response in COVID-19.
    Park SH
    Mol Cells; 2021 Jun; 44(6):384-391. PubMed ID: 34098591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms.
    Sanghai N; Tranmer GK
    Drug Discov Today; 2020 Dec; 25(12):2076-2079. PubMed ID: 32949526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytokines and COVID-19: friends or foes?
    Rokni M; Hamblin MR; Rezaei N
    Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.